| Half-life | 35 hours |
| Tmax | 4 h |
| Bioavailability | 80 % (approx) |
| Protein Binding | 80 % |
| Volume of Distribution | 12 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | FDA recommends maximum 20 mg/day in elderly or hepatic impairment due to QT risk. CYP2C19 interactions increase QT risk. |
Severity: Moderate
Adverse Effects:
QT prolongation, sexual dysfunction, nausea, insomnia
Contraindications:
Concomitant MAOI use; congenital long QT syndrome
Precautions:
Monitor ECG in high-risk patients; avoid >40 mg/day; reduce dose to 20 mg/day in elderly/hepatic impairment.